Enveric Biosciences (NASDAQ:ENVB) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Enveric Biosciences (NASDAQ:ENVB) from a sell rating to a hold rating in a research note released on Sunday morning.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Enveric Biosciences in a research report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Enveric Biosciences has a consensus rating of “Sell”.

Enveric Biosciences Stock Performance

Shares of NASDAQ ENVB opened at $1.43 on Friday. Enveric Biosciences has a 12-month low of $1.25 and a 12-month high of $17.64. The stock has a market cap of $6.41 million, a PE ratio of -0.11 and a beta of 1.13. The company has a 50-day moving average of $1.41 and a 200 day moving average of $2.03.

Enveric Biosciences (NASDAQ:ENVB) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.76) EPS for the quarter.

Enveric Biosciences Company Profile

Enveric Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations.

Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety.